SCHEMBL955995

SCHEMBL955995

Cc1ccccc1S(=O)(=O)NC(=O)Nc1nc2c(Cl)cccc2s1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FBP1 P09467 1/20 0.56
ACP1 P24666 3/20 0.53
MAPT P10636 5/20 0.49
KMT2A Q03164 4/20 0.49
ALDH1A1 P00352 4/20 0.49
MEN1 O00255 3/20 0.49
HPGD P15428 2/20 0.49
KDM4E B2RXH2 1/20 0.49
GAA P10253 2/20 0.48
MAPK1 P28482 4/20 0.47
TSHR P16473 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
PKM P14618 3/20 0.47
SENP7 Q9BQF6 1/20 0.47
LMNA P02545 3/20 0.47
ALOX15 P16050 1/20 0.47
TDP1 Q9NUW8 1/20 0.46
HTT P42858 1/20 0.46
ADORA2A P29274 1/20 0.45
CA12 O43570 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL959411 0.84 ACP1 (0.65) FBP1ACP1MAPTKMT2AALDH1A1
SCHEMBL957109 0.80 FBP1 (0.58) FBP1ACP1MAPTKMT2AMEN1
SCHEMBL30754208 0.75 DYRK1A (0.71) ACP1MAPTKMT2AALDH1A1MEN1
SCHEMBL958370 0.74 FBP1 (0.60) FBP1MAPTKMT2AALDH1A1MEN1
SCHEMBL4917839 0.74 KMT2A (0.57) ACP1MAPTKMT2AALDH1A1MEN1
SCHEMBL2754060 0.73 KMT2A (0.67) ACP1MAPTKMT2AALDH1A1MEN1
SCHEMBL11714671 0.72 MAPT (0.60) ACP1MAPTKMT2AALDH1A1MEN1
SCHEMBL960358 0.72 MAPT (0.66) MAPTKMT2AALDH1A1MEN1HPGD
SCHEMBL15756371 0.72 MAPK1 (0.62) ACP1MAPTKMT2AALDH1A1MEN1
SCHEMBL960410 0.72 FBP1 (0.54) FBP1ACP1ALDH1A1KDM4ECA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7868030-B2 FBPase inhibitors for diabetes HOFFMANN-LA ROCHE INC. (US) 2011-01-11 US claimed
EP-2032548-A1 THIAZOLE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2009-03-11 EP claimed
WO-2007137962-A1 THIAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-12-06 WO claimed
US-20070281979-A1 Fructose-1,6-bisphosphatase (FBPase) inhibitors, such as N-[(5-bromo-1,3-thiazol-2-yl)carbamoyl]3(difluoromethoxy)benzenesulfonamide, used as antidiabetic agents HOFFMANN-LA ROCHE INC. 2007-12-06 US claimed
US-7868030-B2 FBPase inhibitors for diabetes HOFFMANN-LA ROCHE INC. (US) 2011-01-11 US disclosed
EP-2032548-A1 THIAZOLE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2009-03-11 EP disclosed
WO-2007137962-A1 THIAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-12-06 WO disclosed
US-20070281979-A1 Fructose-1,6-bisphosphatase (FBPase) inhibitors, such as N-[(5-bromo-1,3-thiazol-2-yl)carbamoyl]3(difluoromethoxy)benzenesulfonamide, used as antidiabetic agents HOFFMANN-LA ROCHE INC. 2007-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281979-A1 Fructose-1,6-bisphosphatase (FBPase) inhibitors, such as N-[(5-bromo-1,3-thiazol-2-yl)carbamoyl]3(difluoromethoxy)benzenesulfonamide, used as antidiabetic agents FBP1, PFKFB1, PFKFB3 FBP1 1/4885ACP1 1997/4885MAPT 3081/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.